Travere Therapeutics, Inc.
TVTXNext catalyst
Sparsentan
Focal Segmental Glomerulosclerosis
Get an email about TVTX's next catalysts
Track Travere Therapeutics (TVTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
3 upcoming, 1 past
Sparsentan Phase 2 Est. Readout (EPPIK)
Primary completion for Sparsentan trial (NCT05003986) in Focal Segmental Glomerulosclerosis
SourcePegtibatinase Phase 2 Est. Readout
Estimated primary completion for Pegtibatinase trial (NCT03406611) in Homocystinuria. Topline data typically follows completion by weeks to months.
SourcePegtibatinase Phase 3 Est. Readout (HARMONY)
Estimated primary completion for Pegtibatinase trial (NCT06247085) in Homocystinuria. Topline data typically follows completion by weeks to months.
SourceHow TVTX's past catalysts played out
Market Overview
Stock performance and key metrics
Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
Irbesartan
Focal Segmental Glomerulosclerosis
Pegtibatinase
Homocystinuria
Sparsentan
Focal Segmental Glomerulosclerosis
Dapagliflozin
Immunoglobulin A Nephropathy
RE-021 (Sparsentan)
Focal Segmental Glomerulosclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Irbesartan | Phase 3 | Focal Segmental Glomerulosclerosis | - | - |
Pegtibatinase | Phase 3 | Homocystinuria | - | - |
Sparsentan | Phase 3 | Focal Segmental Glomerulosclerosis | - | - |
Dapagliflozin | Phase 3 | Immunoglobulin A Nephropathy | - | - |
RE-021 (Sparsentan) | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
Frequently asked questions
What is in Travere Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Travere Therapeutics, Inc.'s (TVTX) pipeline across Phase 3, Phase 2. Its lead program is Pegtibatinase (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Travere Therapeutics, Inc.'s next FDA catalyst?→
Travere Therapeutics, Inc.'s (TVTX) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TVTX biotech catalysts?→
Add TVTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Travere Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
